Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Gastritis-II: Pathophysiology01:17

Gastritis-II: Pathophysiology

1.9K
Gastritis is marked by disruption of the mucosal barrier that usually protects the stomach tissue from digestive juices and manifests in acute and chronic forms.
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
1.9K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

386
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
386
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

274
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
274
Gastritis II: Pathophysiology01:26

Gastritis II: Pathophysiology

87
The pathophysiology of gastritis begins with the colonization of the stomach lining by Helicobacter pylori (H. pylori). This bacterium spreads mainly via the oral-oral route through saliva or shared utensils, and can also be transmitted in overcrowded or unhygienic environments through contaminated water, despite its brief survival outside the body.ColonizationOnce ingested, H. pylori enters the stomach and begins colonization by navigating through the mucus layer lining the stomach wall. It...
87
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

49
Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to...
49
Jaundice01:25

Jaundice

44
Jaundice, or icterus, is the yellow discoloration of the skin, sclerae, and mucous membranes. It happens when plasma bilirubin levels rise above 2.5-3 mg/dL, leading to bilirubin deposition in tissue.Bilirubin is a byproduct of hemoglobin degradation. In macrophages, hemoglobin breaks down into globin and heme. Globin is converted into amino acids, while heme is turned into biliverdin by heme oxygenase, which is then reduced to unconjugated bilirubin by biliverdin reductase.Unconjugated...
44

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Association Between Ventricular-Arterial Coupling and C-Reactive Protein in Patients at Risk for Heart Failure.

Circulation journal : official journal of the Japanese Circulation Society·2026
Same author

Targeting MLL1/WDR5-Mediated Epigenetic Regulation Mitigates Peritoneal Fibrosis by Reducing p16<sup>INK4a</sup>.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology·2025
Same author

Effects of low-intensity pulsed ultrasound on clinical parameters in atherosclerotic peripheral artery disease patients with chronic limb-threatening ischemia.

Scientific reports·2025
Same author

Eplerenone, diabetes, and chronic kidney disease in patients hospitalized for acute heart failure: findings from the EARLIER trial.

Cardiovascular diabetology·2025
Same author

A Severe Case of Rhabdomyolysis Requiring Renal Replacement Therapy Following COVID-19 mRNA Vaccination.

Internal medicine (Tokyo, Japan)·2025
Same author

Responses of the carotid artery to acute, fractionated or chronic ionizing irradiation, and differences from the aorta.

Scientific reports·2025

関連する実験動画

Updated: May 6, 2026

In vivo Liver Endocytosis Followed by Purification of Liver Cells by Liver Perfusion
12:35

In vivo Liver Endocytosis Followed by Purification of Liver Cells by Liver Perfusion

Published on: November 10, 2011

20.3K

ハイパービリルビネミア,内皮機能の増強,ギルバート症候群における酸化ストレス減少

Tatsuya Maruhashi1, Junko Soga, Noritaka Fujimura

  • 1Department of Cardiovascular Medicine, Hiroshima University Graduate School of Biomedical Sciences, Hiroshima, Japan.

Circulation
|July 10, 2012
PubMed
まとめ

ギルバート症候群の個人は,高レベルのビリルビンにより,酸化ストレスが軽減され,内皮機能が改善されます. これはビリルビリンを示唆しています.

さらに関連する動画

Quantification of Reactive Oxygen Species Using 2&#8242;,7&#8242;-Dichlorofluorescein Diacetate Probe and Flow-Cytometry in M&#252;ller Glial Cells
14:25

Quantification of Reactive Oxygen Species Using 2′,7′-Dichlorofluorescein Diacetate Probe and Flow-Cytometry in Müller Glial Cells

Published on: May 13, 2022

6.2K
Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug
05:57

Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug

Published on: May 17, 2024

1.3K

関連する実験動画

Last Updated: May 6, 2026

In vivo Liver Endocytosis Followed by Purification of Liver Cells by Liver Perfusion
12:35

In vivo Liver Endocytosis Followed by Purification of Liver Cells by Liver Perfusion

Published on: November 10, 2011

20.3K
Quantification of Reactive Oxygen Species Using 2&#8242;,7&#8242;-Dichlorofluorescein Diacetate Probe and Flow-Cytometry in M&#252;ller Glial Cells
14:25

Quantification of Reactive Oxygen Species Using 2′,7′-Dichlorofluorescein Diacetate Probe and Flow-Cytometry in Müller Glial Cells

Published on: May 13, 2022

6.2K
Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug
05:57

Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug

Published on: May 17, 2024

1.3K

科学分野:

  • 心血管科学 心血管科学
  • エンドクリノロジー エンドクリノロジー
  • メタボリック障害 メタボリック障害

背景:

  • ギルバート症候群は,軽度の非結合性高bilirubinemiaによって特徴付けられています.
  • ビリルビンは,内生的な抗酸化物質として認識されています.
  • この研究では,心血管疾患のリスク因子を持たないギルバート症候群患者の酸化ストレスが調査されています.

研究 の 目的:

  • ギルバート症候群の患者の内皮機能における酸化ストレスの役割を評価する.
  • 血管の健康に対する高bilirubinemiaの影響を評価するために.
  • ビリルビンの濃度,酸化ストレスマーカー,内皮機能の関係を見極める.

主な方法:

  • ギルバート症候群の男性108人と,健康な対照群108人を対象とした研究.
  • 血清ビリルビン,マロンディアルデヒド改変低密度リポタンパク質 (MDA-LDL),尿中の8-ヒドロキシ-2'-デオキシグアノシン (8-OHdG) を酸化ストレスマーカーとして測定.
  • 内皮機能の評価のために,フローメディエイト血管拡張 (FMD) の評価.

主要な成果:

  • ギルバート症候群の患者は血清ビリルビン濃度 (P<0.001) が著しく高かった.
  • 酸化ストレスマーカー (MDA-LDLと8-OHdG) の低いレベルは,ギルバート症候群の患者に観察されました (P=0.034とP=0.001,それぞれ).
  • ギルバート症候群の患者では,対照群 (P<0.001) と比較して,フローメディエイト血管拡張の強化が認められた.

結論:

  • ギルバート症候群は,酸化ストレスが軽減され,ビリルビンのレベルが上昇する.
  • ギルバート症候群における超bilirubinemiaは,内皮に依存した血管拡張の改善と相関しています.
  • これらの発見は,血管の健康におけるビリルビンの潜在的な保護的役割を強調しています.